UNITUXIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for UNITUXIN (UNITUXIN).
Dinutuximab is a chimeric monoclonal antibody that binds to the disialoganglioside GD2, which is overexpressed on neuroblastoma cells. Binding to GD2 induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
| Metabolism | Dinutuximab is a monoclonal antibody; it is expected to be degraded into small peptides and amino acids via catabolic pathways. No specific CYP450 enzyme involvement. |
| Excretion | Unchanged drug: negligible renal excretion; metabolism and biliary/fecal elimination are the primary routes. Specific % not established; in clinical studies, <1% of dose recovered in urine as parent drug. |
| Half-life | Terminal half-life approximately 22.6 days (range 11.4–45.3 days) in pediatric patients; supports every-other-week dosing. Half-life is prolonged compared to adults due to slower clearance in children. |
| Protein binding | Approximately 99.7% bound to human serum proteins; primarily binds to albumin and beta-2-glycoprotein I. |
| Volume of Distribution | Estimated Vdss approximately 4.5 L (not weight-normalized; corresponds to ~0.06 L/kg in a 70 kg adult) indicating limited extravascular distribution. |
| Bioavailability | Only intravenous administration; bioavailability 100% by IV route. |
| Onset of Action | Intravenous: Clinical effects (inhibition of GD2-mediated tumor growth) observed within 2–3 weeks after initiation of therapy; not applicable for immediate symptom relief. |
| Duration of Action | Pharmacodynamic effects persist for several weeks after last dose due to long half-life; clinical duration of response varies by tumor type and combination therapy. No standard duration defined. |
1,500 mg/m² intravenously over 1 hour on days 1, 8, and 15 of each 28-day cycle.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment recommended; use caution in severe renal impairment (CrCl < 30 mL/min) due to limited data. |
| Liver impairment | No specific dose adjustment for Child-Pugh Class A or B; not studied in Child-Pugh Class C. |
| Pediatric use | Weight-based dosing: for patients ≤ 30 kg, 1,500 mg/m²; safety and efficacy not established in pediatric patients < 18 years. |
| Geriatric use | No specific dose adjustment; elderly patients may have increased risk of infusion-related reactions and renal impairment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for UNITUXIN (UNITUXIN).
| Breastfeeding | It is unknown whether dinutuximab is excreted in human milk. Human IgG is present in colostrum and breast milk, but it is degraded in the infant's gastrointestinal tract. However, neonatal Fc receptors may allow absorption. M/P ratio is not available. Because of the potential for serious adverse reactions (e.g., severe neuropathic pain, cytopenias) in the breastfed infant, women should not breastfeed during treatment and for at least 6 months after the last dose. |
| Teratogenic Risk | Unituxin (dinutuximab) is a monoclonal antibody (IgG1) that can cross the placenta. Based on its mechanism of action (GD2-directed), it is expected to cause fetal harm. In animal studies, administration during organogenesis resulted in embryolethality and structural abnormalities. First trimester: Avoid exposure due to risk of teratogenesis. Second/Third trimester: Risk of fetal GD2-positive tissue destruction; may cause fetal neurotoxicity and autonomic dysfunction. Contraindicated in pregnancy. |
■ FDA Black Box Warning
No FDA black box warning exists for dinutuximab.
| Serious Effects |
["History of anaphylactic reactions to dinutuximab or any of its excipients."]
| Precautions | ["Severe neuropathic pain requiring opioid analgesia; premedicate with opioids.","Capillary leak syndrome, which may be life-threatening.","Hypotension, hypertension, and tachycardia; monitor vital signs.","Peripheral neuropathy including sensory and motor deficits.","Serious infections, including sepsis.","Reversible posterior leukoencephalopathy syndrome (RPLS).","Infusion-related reactions including anaphylaxis."] |
Loading safety data…
| Fetal Monitoring | Monitor for maternal infusion reactions, hypotension, capillary leak syndrome, and neurotoxicity. Fetal monitoring: Ultrasound for growth and amniotic fluid volume; assess for fetal hydrops or structural anomalies if exposure occurred. Newborns should be evaluated for persistent GD2 antibody binding and potential autonomic dysfunction. |
| Fertility Effects | In animal studies, dinutuximab did not directly impair fertility, but chronic inflammation and immune modulation may indirectly affect reproductive function. In humans, no dedicated fertility studies are available. Patients should be counseled about potential effects on ovarian or testicular function, especially with prolonged use. |